Lenalidomide
Showing 1 - 25 of 1,018
Multiple Myeloma Trial in Torino (Melphalan, Prednisone, Lenalidomide, Cyclophosphamide, Prednisone, Lenalidomide, Lenalidomide,
Active, not recruiting
- Multiple Myeloma
- Melphalan, Prednisone, Lenalidomide
- +2 more
-
Torino, TO, ItalyDivision Of Hematology, A.O.U. Città della Salute e della Scienz
Mar 24, 2022
Oral Ulcer Trial in Beijing (Lenalidomide 10 mg)
Not yet recruiting
- Oral Ulcer
- Lenalidomide 10 mg
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Jul 5, 2022
Waldenström's Macroglobulinemia Trial in Busan (Lenalidomide, Bortezomib, Rituximab, Dexamethasone)
Recruiting
- Waldenström's Macroglobulinemia
- Lenalidomide, Bortezomib, Rituximab, Dexamethasone
-
Busan, Sue-gu, Korea, Republic ofKosin University Gospel Hospital
Mar 31, 2022
Dermatomyositis Trial in Nanchang (Lenalidomide)
Not yet recruiting
- Dermatomyositis
- Lenalidomide
-
Nanchang, Jiangxi, ChinaDepartment of Rheumatology and Clinical Immunology, Jiangxi Prov
Aug 3, 2022
Diffuse Large-cell B-cell Lymphoma Trial in Seattle (plamotamab, tafasitamab, lenalidomide)
Recruiting
- Diffuse Large-cell B-cell Lymphoma
- plamotamab
- +2 more
-
Seattle, WashingtonSwedish Cancer Center
May 2, 2022
Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)
Not yet recruiting
- Non-Hodgkin Lymphoma
- Tafasitamab
- +3 more
-
Cologne, GermanyUniversity of Cologne
Oct 14, 2022
Follicular Lymphoma and Marginal Zone Lymphoma Trial in Beijing (Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide,
Recruiting
- Follicular Lymphoma and Marginal Zone Lymphoma
- Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide
- lenalinomide
-
Beijing, ChinaChinese Academy of Medical Sciences and Peking Union Medical Col
Feb 13, 2022
CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)
Recruiting
- CNS Lymphoma
- +2 more
- Tafasitamab
- Lenalidomide
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 10, 2022
Multiple Myeloma Trial in Seoul (Lenalidomide maintenance)
Recruiting
- Multiple Myeloma
- Lenalidomide maintenance
-
Seoul, Korea, Republic ofSamsung Medical Center
Aug 10, 2022
Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL Trial in Houston (Mosunetuzumab, Polatuzumab vedotin, Tafasitamab)
Not yet recruiting
- Hodgkin Lymphoma
- +2 more
- Mosunetuzumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Nov 7, 2022
Multiple Myeloma Trial in Busan (Lenalidomide, Dexamethasone)
Recruiting
- Multiple Myeloma
- Lenalidomide
- Dexamethasone
-
Busan, Western, Korea, Republic ofKosin University Gospel Hospital
Mar 31, 2022
DLBCL Trial in Hangzhou (Tafasitamab and Lenalidomide)
Recruiting
- DLBCL
- Tafasitamab and Lenalidomide
-
Hangzhou, Zhejiang, ChinaThe First Afflicated Hospital, College of Medicine, Zhejiang Uni
Sep 21, 2022
CNS Lymphoma Trial in Zhengzhou (Rituximab, Lenalidomide, Zanubrutinib, Lenalidomide, Zanubrutinib, Lenalidomide)
Recruiting
- Central Nervous System Lymphoma
- Rituximab, Lenalidomide, Zanubrutinib
- +2 more
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Jun 16, 2021
Multiple Myeloma Trial in Worldwide (Elranatamab, Daratumumab, Lenalidomide)
Recruiting
- Multiple Myeloma
- Elranatamab
- +3 more
-
Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
- +7 more
Jan 9, 2023
Mantle Cell Lymphoma, Untreated Trial in United States (Lenalidomide, R-CHOP, high-dose cytarabine (HIDAC))
Active, not recruiting
- Mantle Cell Lymphoma
- Untreated
- Lenalidomide
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Feb 17, 2022
Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Epcoritamab
- Lenalidomide
- (no location specified)
Jan 20, 2023
Plasma Cell Myeloma, Transplant-Related Carcinoma Trial in Seattle (Ixazomib Citrate, Laboratory Biomarker Analysis,
Active, not recruiting
- Plasma Cell Myeloma
- Transplant-Related Carcinoma
- Ixazomib Citrate
- +2 more
-
Seattle, WashingtonFred Hutchinson Cancer Research Center
Jul 12, 2022
Multiple Myeloma Trial in Worldwide (Teclistamab, Lenalidomide)
Not yet recruiting
- Multiple Myeloma
- Teclistamab
- Lenalidomide
-
Melbourne, Australia
- +13 more
Feb 7, 2022
Acute Myeloid Leukemia Trial in Chapel Hill (Lenalidomide)
Completed
- Acute Myeloid Leukemia
- Lenalidomide
-
Chapel Hill, North CarolinaUniversity of North Carolina at Chapel Hill - Lineberger Compreh
Jan 25, 2022
Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease, Histiocytic Sarcoma (HS) Trial in Boston
Active, not recruiting
- Langerhans Cell Histiocytosis (LCH)
- +2 more
- Lenalidomide
-
Boston, MassachusettsDana-Farber Cancer Institute
Feb 11, 2022
Overall Survival Trial in Qingdao (Rituximab + zanubrutinib + lenalidomide)
Recruiting
- Overall Survival
- Rituximab + zanubrutinib + lenalidomide
-
Qingdao, Shandong, ChinaQingdao central Hospital
May 22, 2022
Multiple Myeloma Trial in Chicago, Detroit, Poznan (Lenalidomide, Carfilzomib, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Lenalidomide
- +3 more
-
Chicago, Illinois
- +2 more
Jun 29, 2021